The AMA’s submission to Health Technology Assessment (HTA) Policy and Methods Review – Consultation 1 was published this week. The HTA review is being conducted over 2023 with the aim of reducing the time it takes to make new health technologies accessible and ensuring our assessment processes are fit for purpose. The AMA supports the aims and the purpose of the review.
The submission details the AMA’s support for the HTA’s review process and outcomes — the listings of medicines on the PBS and addition of MBS items that accompany the use of therapeutics and devices — as central to the tasks of medical practitioners, as well as providing patients with safe and affordable access to essential treatments.
The AMA also supports the role played by practitioners in the decision-making processes of the HTA, ensuring decisions are made with an eye to best clinical governance and appropriate concern for judicious use of resources.
